<DOC>
	<DOCNO>NCT02049866</DOCNO>
	<brief_summary>The purpose research study evaluate antiresorptive therapy denosumab ( Prolia ) prevention bone loss stop teriparatide ( TPTD ) premenopausal woman idiopathic osteoporosis . Premenopausal woman receive TPTD FDA Orphan Diseases Program-funded trial , `` A Phase 2 Study Teriparatide Treatment Idiopathic Osteoporosis Premenopausal Women '' ( NCT01440803 ) may eligible participate current study , 36-month open-label pilot study denosumab ( ProliaÂ® , 60mg SC every 6 month ) . The goal study estimate effect denosumab central peripheral , well trabecular cortical , bone mass microstructure obtain preliminary data inform design future randomize study . This study present first opportunity study effect denosumab TPTD unique severely affect group young woman . Funding Source - FDA OOPD</brief_summary>
	<brief_title>Denosumab Prevention Post-Teriparatide Bone Loss Premenopausal Women With IOP</brief_title>
	<detailed_description>Osteoporosis premenopausal woman normal menstrual function specific cause term idiopathic osteoporosis ( IOP ) . IOP rare disease estimate prevalence &lt; 200,000 affect premenopausal woman United States . Denosumab , potent inhibitor osteoclast-mediated bone resorption , lead continuous gain trabecular cortical bone mineral density ( BMD ) . Moreover , denosumab retain skeleton , may thus preferable use young woman may contemplate future pregnancy . The investigator hypothesize denosumab , initiate completion two year TPTD , maintain improve central peripheral areal volumetric BMD , microstructure stiffness premenopausal woman IOP .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>All woman complete NCT01440803 remain without disease medication cause osteoporosis offer enrollment study . ( Premenopausal status longer require entry . ) Renal insufficiency liver disease : Creatinine , transaminase ( AST ) /alanine transaminase ( ALT ) upper limit normal Vitamin D deficiency : 25hydroxyvitamin D ( 25OHD ) &lt; 30 ng/mL Pregnancy : urine pregnancy test must negative</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>premenopausal</keyword>
	<keyword>denosumab</keyword>
	<keyword>idiopathic</keyword>
	<keyword>Idiopathic Osteoporosis Premenopausal Women</keyword>
</DOC>